Table 2 Clinical characteristics and peri-operative data of patie

18 pts) BAL LRP (n. 34 pts) BAL RALP (n. 14 pts) P Clinical data              Age (yrs) 61.4 (5.7) 59.5 (6.7) 63.2 (5.8) 60.1 (7.7) 0.25    ASA, n (%):              I 3 (8.3%) 1 (5.6%) 5 (14.7%) 1 (7.1%) 0.68    II 33 (91.7%) 17 (94.4%) 29 (85.3%) 13 (92.9%)      Histological grade of cancer              G2 (Gleason 5–6) 9 (25.0%) 6 (33.3%) 10 (29.4) 4 (28.6) 0.93    G3 (Gleason 7–10) 27 (75.0%) 12 (66.7%) 24 (70.6%) 10 www.selleckchem.com/products/icg-001.html (71.4%)      pT, n (%)              2 12 (33.3%)

18 (100%) 18 (52.9%) 14 R788 ic50 (100%) 0.001    3 24 (66.7%) 0 16 (47.1%) 0      pN, n (%)*              0 11 (84.6%) 6 (85.7%) 14 (93.3%) 10 (100%) 0.57    1 2 (15.4%) 1 (14.3%) 1 (6.7%) 0   Perioperative data              Time of anaesthesia (min) 104.0 (21.3) 109.7 (24.4) 98.8 (30.2) 105.2 (24.8) 0.32    Blood loss (ml) 119.2 (140.3) 128.3 (150.1) 118.2 (121.4) 125.2 (131.5) 0.30   Total amount of crystalloid received (ml) 475.4 (100.4) 460.8 (118.4) 486.1 (166.4) 499.8 (200.2) 0.21    Intra-operative body temperature 36.2 (0.3) 36.1 (0.4) 36.1 (0.2) 36.1 (0.3) 0.87    Intra-operative MAP (mmHg) 103.8 (11.8) 105.3 (12.5) 105.4 (12.4) 106.8 (12.2) 0.54    Intra-operative SpO2 (%) 96.7 (0.9) 96.7 (0.9) 97.8

(1.8) 97.8 (1.8) 0.75    Arterial lactate level (mmol/l)              1 h post-surgery 0.7 (0.2) 0.7 (0.3) 0.6 (0.3) 0.6 (0.4) 0.81    24 h post-sugery 1.8 (0.3) 1.7 (0.2) 1.7 (0.3) 1.8 (0.3) 0.77    Intra-operative BE (mmol/l) 0.3 (0.4) 0.4 (0.3) 0.3 (0.4) 0.4 (0.3) 0.78    Intra-operative PaO2 (mmHg) 220.6 (13.2) 218.8 (13.4) 214.6 (18.6) 219.5 (19.0) 0.22 Values are expressed in absolute values or mean (SD). Abbreviations: TIVA-TCI total intravenous anaesthesia with target-controlled infusion, BAL balanced inhalation second anaesthesia, LRP laparoscopic

radical prostatectomy, RALP robot-assisted selleckchem laparoscopic prostatectomy. *Lymph node dissection was made in 45 out of 102 pts. Thirty-two out of 102 patients (31.4%) underwent RALP and were equally distributed between the TIVA-TCI and BAL. The lymph node dissection was made in 45 out of 102 pts (44.1%). All patients were at highest risk of venous thromboembolism, according to the model proposed by Caprini et al. [25] and Bergqvist et al. [26] (being all neoplastic and undergoing surgery); 10 of these (9.8%) had an ASA I whereas 92 (90.2%) an ASA II. Thirty-nine patients of TIVA-TCI group (72.2%) and 34 of BAL group (70.8%) showed a high grade prostatic carcinoma (G3) with Gleason score ≥7.

Comments are closed.